Lauren Sciences LLC news

New York, N.Y., April 11, 2018 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart^® Nanomedicines for brain diseases, today announced the award of its third grant from The ALS Association. The ALS Association grant will support Lauren Sciences continued development of LAUR-301, its novel V-Smart^® Nanomedicine for ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig`s disease. Future success of LAUR-301 is

New York, New York, February 7, 2017 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart^™ Nanomedicines for brain diseases, today announced the award of its second grant from Voices Against Brain Cancer (VABC). VABC grant will support Lauren Sciences continued development of LAUR-401, its novel V-Smart^™ Nanomedicine for Glioblastoma Multiforme (GBM). Future success of LAUR-401 should provide an effective new tr

New York, N.Y., April 19, 2016 -- Lauren Sciences LLC, private New York biotechnology company developing breakthrough V-Smart^TM Nanomedicines for brain diseases, announced today award of second grant from The ALS Association. The ALS Association grant will support Lauren Sciences continued development of LAUR-301, its V-Smart^TM Nanomedicine designed for ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig`s disease.

Lauren Sciences developed LAUR-301, wi

New York, New York, June 30, 2015 -- Lauren Sciences LLC, the private New York biotechnology company developing breakthrough V-Smart™ Nanomedicines for brain diseases, announced today the award of a grant by Voices Against Brain Cancer (VABC). VABC funding will support the development of a V-Smart™ for glioblastoma multiforme (GBM). The future success of V-Smart™ for GBM should provide an effective new treatment for GBM patients.

V-Smart™ for GBM will target an

New York, N.Y., August 12, 2014 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ therapeutics, with its innovative V-Smart™ targeted drug delivery system, based upon its novel V-Smart™ nanovesicle platform technology, announced the award of a grant today from The ALS Association to its research team at Ben-Gurion University. The ALS Association grant will support development of a V-Smart™ therapeutic for ALS (amyotro

New York, N.Y., October 22, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of V-Smart™ therapeutics based upon its novel nanovesicle platform technology, announced today successful completion by its research team at Ben-Gurion University of the first stage of developing a V-Smart™ therapeutic for the treatment of neuro-HIV. The development of this V-Smart™ therapeutic, that systemically delivers tenofovir across the blood brain bar

New York, N.Y., June 25, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company continuing development of its novel V-Smart™ platform technology, announced today the award of a second grant by The Michael J. Fox Foundation for Parkinson`s Research (MJFF). The company recently completed the first stage of developing V-Smart™-based therapeutics for the treatment of Parkinson`s disease (PD), which was funded by MJFF, whereby it demonstrated targeted delivery of GDNF (gli

New York, N.Y., June 18, 2013 -- Lauren Sciences, a privately-held biotechnology company furthering development of its novel V-Smart™ nanovesicle platform technology, announced today that it was independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in a new report by MCD Group.

The report, "Early Stage Drug Delivery Technologies: Profile